{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:17:22Z","timestamp":1767143842232,"version":"build-2238731810"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T00:00:00Z","timestamp":1409184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40256-014-0087-y","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T02:46:16Z","timestamp":1409107576000},"page":"423-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Thiazide-Like\/Calcium Channel Blocker Agents: A Major Combination for Hypertension Management"],"prefix":"10.1007","volume":"14","author":[{"given":"M. E.","family":"Safar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Blacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,28]]},"reference":[{"issue":"17","key":"87_CR1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","volume":"126","author":"Q Gu","year":"2012","unstructured":"Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126(17):2105\u201314. doi: 10.1161\/CIRCULATIONAHA.112.096156 .","journal-title":"Circulation"},{"issue":"6","key":"87_CR2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jash.2013.07.005","volume":"7","author":"F Thomas","year":"2013","unstructured":"Thomas F, Pannier B, Safar ME. Impact of country of birth on progression of steady and pulsatile hemodynamic parameters in normotensive and hypertensive subjects. J Am Soc Hypertens. 2013;7(6):440\u20137. doi: 10.1016\/j.jash.2013.07.005 .","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"87_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/jhh.2009.34","volume":"24","author":"J Blacher","year":"2010","unstructured":"Blacher J, Evans A, Arveiler D, Amouyel P, Ferrieres J, Bingham A, et al. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J Hum Hypertens. 2010;24(1):19\u201326. doi: 10.1038\/jhh.2009.34 .","journal-title":"J Hum Hypertens"},{"issue":"6","key":"87_CR4","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/HJH.0b013e3283535993","volume":"30","author":"G Tocci","year":"2012","unstructured":"Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, Ferrucci A, et al. Blood pressure control in Italy: analysis of clinical data from 2005\u20132011 surveys on hypertension. J Hypertens. 2012;30(6):1065\u201374. doi: 10.1097\/HJH.0b013e3283535993 .","journal-title":"J Hypertens"},{"issue":"9","key":"87_CR5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1161\/01.CIR.103.9.1245","volume":"103","author":"SS Franklin","year":"2001","unstructured":"Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9):1245\u20139.","journal-title":"Circulation"},{"issue":"18","key":"87_CR6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa003417","volume":"345","author":"RS Vasan","year":"2001","unstructured":"Vasan RS, Larson MG, Leip EP, Evans JC, O\u2019Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"87_CR7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archinte.160.8.1085","volume":"160","author":"J Blacher","year":"2000","unstructured":"Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med. 2000;160(8):1085\u20139.","journal-title":"Arch Intern Med"},{"issue":"5","key":"87_CR8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/HJH.0b013e32835ed5b9","volume":"31","author":"ME Safar","year":"2013","unstructured":"Safar ME, Nilsson PM. Pulsatile hemodynamics and cardiovascular risk factors in very old patients: background, sex aspects and implications. J Hypertens. 2013;31(5):848\u201357. doi: 10.1097\/HJH.0b013e32835ed5b9 .","journal-title":"J Hypertens"},{"key":"87_CR9","unstructured":"National Clinical Guideline Centre. Hypertension. Clinical management of primary hypertension in adults (NICE clinical guideline 127). London, 2011."},{"issue":"1","key":"87_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2014.868629","volume":"23","author":"G Mancia","year":"2014","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH\/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23(1):3\u201316. doi: 10.3109\/08037051.2014.868629 .","journal-title":"Blood Press"},{"key":"87_CR11","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","volume":"346","author":"H Makani","year":"2013","unstructured":"Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360. doi: 10.1136\/bmj.f360 .","journal-title":"BMJ"},{"issue":"5","key":"87_CR12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/jhh.2009.76","volume":"24","author":"M Thoenes","year":"2010","unstructured":"Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Bohm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24(5):336\u201344. doi: 10.1038\/jhh.2009.76 .","journal-title":"J Hum Hypertens"},{"issue":"5","key":"87_CR13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/j.1875-9114.2012.01031.x","volume":"32","author":"N Olson","year":"2012","unstructured":"Olson N, DeJongh B, Hough A, Parra D. Plasma renin activity-guided strategy for the management of hypertension. Pharmacotherapy. 2012;32(5):446\u201355. doi: 10.1002\/j.1875-9114.2012.01031.x .","journal-title":"Pharmacotherapy"},{"issue":"4","key":"87_CR14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/HYP.0000000000000003","volume":"63","author":"AS Go","year":"2014","unstructured":"Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, et al. An effective approach to high blood pressure control: a science advisory from the American heart association, the American college of cardiology, and the centers for disease control and prevention. Hypertension. 2014;63(4):878\u201385. doi: 10.1161\/HYP.0000000000000003 .","journal-title":"Hypertension"},{"issue":"9311","key":"87_CR15","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995\u20131003.","journal-title":"Lancet"},{"issue":"6","key":"87_CR16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ajh\/hpt034","volume":"26","author":"JE Sealey","year":"2013","unstructured":"Sealey JE, Alderman MH, Furberg CD, Laragh JH. Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am J Hypertens. 2013;26(6):727\u201338. doi: 10.1093\/ajh\/hpt034 .","journal-title":"Am J Hypertens"},{"issue":"20","key":"87_CR17","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehr177","volume":"32","author":"PS Sever","year":"2011","unstructured":"Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32(20):2499\u2013506. doi: 10.1093\/eurheartj\/ehr177 .","journal-title":"Eur Heart J"},{"issue":"6","key":"87_CR18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/HJH.0b013e3282fcc37f","volume":"26","author":"T Suonsyrja","year":"2008","unstructured":"Suonsyrja T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T, et al. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. J Hypertens. 2008;26(6):1250\u20136. doi: 10.1097\/HJH.0b013e3282fcc37f .","journal-title":"J Hypertens"},{"issue":"8","key":"87_CR19","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/ajh\/hpt047","volume":"26","author":"GL Schwartz","year":"2013","unstructured":"Schwartz GL, Bailey K, Chapman AB, Boerwinkle E, Turner ST. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens. 2013;26(8):957\u201364. doi: 10.1093\/ajh\/hpt047 .","journal-title":"Am J Hypertens"},{"issue":"13","key":"87_CR20","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","volume":"293","author":"JT Wright Jr","year":"2005","unstructured":"Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293(13):1595\u2013608. doi: 10.1001\/jama.293.13.1595 .","journal-title":"JAMA"},{"issue":"3","key":"87_CR21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0895-7061(00)01266-8","volume":"14","author":"TO Morgan","year":"2001","unstructured":"Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens. 2001;14(3):241\u20137 (S0895-7061(00)01266-8 [pii]).","journal-title":"Am J Hypertens"},{"issue":"19","key":"87_CR22","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","volume":"106","author":"A Zanchetti","year":"2002","unstructured":"Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106(19):2422\u20137.","journal-title":"Circulation"},{"issue":"12","key":"87_CR23","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","volume":"23","author":"L Liu","year":"2005","unstructured":"Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157\u201372 00004872-200512000-00008 [pii].","journal-title":"J Hypertens"},{"issue":"9426","key":"87_CR24","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022\u201331.","journal-title":"Lancet"},{"issue":"8","key":"87_CR25","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","volume":"29","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29(8):1649\u201359. doi: 10.1097\/HJH.0b013e328348345d .","journal-title":"J Hypertens"},{"key":"87_CR26","unstructured":"Wang W, Ma L, Zhang Y, Liu M, Deng Q, Zhu D, et al. 4\u00a0years outcome of amlodipine plus telmisartan or amlodipine plus diuretics regimen on cardiovascular events in hypertensive patients 13,542: final results of CHIEF trial. In: Hypertension ESo, editor. 23rd European Meeting on Hypertension and Cardiovascular Protection, Milan, Italy; 2013."},{"issue":"6","key":"87_CR27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/14656566.2012.670636","volume":"13","author":"JJ DiNicolantonio","year":"2012","unstructured":"DiNicolantonio JJ. Hydrochlorothiazide: is it a wise choice? Expert Opin Pharmacother. 2012;13(6):807\u201314. doi: 10.1517\/14656566.2012.670636 .","journal-title":"Expert Opin Pharmacother"},{"key":"87_CR28","first-page":"CD003824","volume":"5","author":"VM Musini","year":"2014","unstructured":"Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824. doi: 10.1002\/14651858.CD003824.pub2 .","journal-title":"Cochrane Database Syst Rev"},{"key":"87_CR29","doi-asserted-by":"crossref","unstructured":"Mortality after 10 1\/2\u00a0years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82(5):1616\u20131628.","DOI":"10.1161\/01.CIR.82.5.1616"},{"issue":"18","key":"87_CR30","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80\u00a0years of age or older. N Engl J Med. 2008;358(18):1887\u201398.","journal-title":"N Engl J Med"},{"issue":"23","key":"87_CR31","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417\u201328.","journal-title":"N Engl J Med"},{"issue":"10","key":"87_CR32","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/14656566.2012.698611","volume":"13","author":"B Waeber","year":"2012","unstructured":"Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother. 2012;13(10):1515\u201326. doi: 10.1517\/14656566.2012.698611 .","journal-title":"Expert Opin Pharmacother"},{"issue":"1B","key":"87_CR33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0002-9343(88)91305-8","volume":"84","author":"GE Plante","year":"1988","unstructured":"Plante GE, Dessurault DL. Hypertension in elderly patients. A comparative study between indapamide and hydrochlorothiazide. Am J Med. 1988;84(1B):98\u2013103.","journal-title":"Am J Med"},{"issue":"3","key":"87_CR34","first-page":"171","volume":"2","author":"R Carretta","year":"1988","unstructured":"Carretta R, Fabris B, Bardelli M, Muiesan S, Fischetti F, Vran F, et al. Arterial compliance and baroreceptor sensitivity after chronic treatment with indapamide. J Hum Hypertens. 1988;2(3):171\u20135.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"87_CR35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjhyper.2005.06.027","volume":"19","author":"G London","year":"2006","unstructured":"London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens. 2006;19(1):113\u201321. doi: 10.1016\/j.amjhyper.2005.06.027 .","journal-title":"Am J Hypertens"},{"issue":"8","key":"87_CR36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/ajh\/hpt081","volume":"26","author":"D Agnoletti","year":"2013","unstructured":"Agnoletti D, Zhang Y, Borghi C, Blacher J, Safar ME. Effects of antihypertensive drugs on central blood pressure in humans: a preliminary observation. Am J Hypertens. 2013;26(8):1045\u201352. doi: 10.1093\/ajh\/hpt081 .","journal-title":"Am J Hypertens"},{"issue":"2","key":"87_CR37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/mol.113.085878","volume":"84","author":"F Ma","year":"2013","unstructured":"Ma F, Lin F, Chen C, Cheng J, Zeldin DC, Wang Y, et al. Indapamide lowers blood pressure by increasing production of epoxyeicosatrienoic acids in the kidney. Mol Pharmacol. 2013;84(2):286\u201395. doi: 10.1124\/mol.113.085878 .","journal-title":"Mol Pharmacol"},{"issue":"1\u20132","key":"87_CR38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1006845612499","volume":"178","author":"C Vergely","year":"1998","unstructured":"Vergely C, Walker MK, Zeller M, Rademakers JR, Maupoil V, Schiavi P, et al. Antioxidant properties of indapamide, 5-OH indapamide and hydrochlorothiazide evaluated by oxygen-radical absorbing capacity and electron paramagnetic resonance. Mol Cell Biochem. 1998;178(1\u20132):151\u20135.","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"87_CR39","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/hy1101.96740","volume":"38","author":"K Et-Taouil","year":"2001","unstructured":"Et-Taouil K, Schiavi P, Levy BI, Plante GE. Sodium intake, large artery stiffness, and proteoglycans in the spontaneously hypertensive rat. Hypertension. 2001;38(5):1172\u20136.","journal-title":"Hypertension"},{"issue":"12","key":"87_CR40","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.ATV.0000097770.66965.2A","volume":"23","author":"RP Mason","year":"2003","unstructured":"Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23(12):2155\u201363. doi: 10.1161\/01.ATV.0000097770.66965.2A .","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"87_CR41","first-page":"115","volume":"5","author":"FP Cappuccio","year":"1991","unstructured":"Cappuccio FP, Markandu ND, Sagnella GA, Singer DR, Buckley MG, Miller MA, et al. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens. 1991;5(2):115\u20139.","journal-title":"J Hum Hypertens"},{"issue":"13","key":"87_CR42","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","volume":"102","author":"B Pitt","year":"2000","unstructured":"Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503\u201310.","journal-title":"Circulation"},{"issue":"18","key":"87_CR43","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217\u201325.","journal-title":"JAMA"},{"issue":"9","key":"87_CR44","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","volume":"113","author":"B Williams","year":"2006","unstructured":"Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213\u201325. doi: 10.1161\/CIRCULATIONAHA.105.595496 .","journal-title":"Circulation"},{"issue":"11","key":"87_CR45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2165\/00044011-200727110-00001","volume":"27","author":"JP Baguet","year":"2007","unstructured":"Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig. 2007;27(11):735\u201353 (27111 [pii]).","journal-title":"Clin Drug Investig"},{"issue":"2","key":"87_CR46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004872-200102000-00023","volume":"19","author":"JP Emeriau","year":"2001","unstructured":"Emeriau JP, Knauf H, Pujadas JO, Calvo-Gomez C, Abate G, Leonetti G, et al. A comparison of indapamide SR 1.5\u00a0mg with both amlodipine 5\u00a0mg and hydrochlorothiazide 25\u00a0mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens. 2001;19(2):343\u201350.","journal-title":"J Hypertens"},{"issue":"12","key":"87_CR47","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1185\/030079907X242674","volume":"23","author":"J Akram","year":"2007","unstructured":"Akram J, Sheikh UE, Mahmood M, Donnelly R. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study. Curr Med Res Opin. 2007;23(12):2929\u201336. doi: 10.1185\/030079907X242674 .","journal-title":"Curr Med Res Opin"},{"key":"87_CR48","unstructured":"Hanon O, Asmar R, Marre M, editors. Benefit of adding amlodipine 5\u00a0mg and 10\u00a0mg to indapamide SR in uncontrolled hypertensive patients with diabetes mellitus. Results of the 1-year NESTOR trial (abstract). 23rd scientific meeting of the European Society of Hypertension, Milan, Italy; 2013."},{"issue":"9718","key":"87_CR49","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)60308-X","volume":"375","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Howard SC, Dolan E, O\u2019Brien E, Dobson JE, Dahlof B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895\u2013905. doi: 10.1016\/S0140-6736(10)60308-X .","journal-title":"Lancet"},{"issue":"2","key":"87_CR50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/HYPERTENSIONAHA.111.174383","volume":"58","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension. 2011;58(2):155\u201360. doi: 10.1161\/HYPERTENSIONAHA.111.174383 .","journal-title":"Hypertension"},{"issue":"5","key":"87_CR51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(10)70066-1","volume":"9","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Howard SC, Dolan E, O\u2019Brien E, Dobson JE, Dahlof B, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469\u201380. doi: 10.1016\/S1474-4422(10)70066-1 .","journal-title":"Lancet Neurol"},{"issue":"10","key":"87_CR52","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00004872-200018100-00015","volume":"18","author":"P Gosse","year":"2000","unstructured":"Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5\u00a0mg versus enalapril 20\u00a0mg: the LIVE study. J Hypertens. 2000;18(10):1465\u201375.","journal-title":"J Hypertens"},{"issue":"3","key":"87_CR53","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005344-199509000-00018","volume":"26","author":"RA Kloner","year":"1995","unstructured":"Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M. Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. J Cardiovasc Pharmacol. 1995;26(3):471\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"87_CR54","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/01.hjh.0000133733.32125.09","volume":"22","author":"M Marre","year":"2004","unstructured":"Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22(8):1613\u201322.","journal-title":"J Hypertens"},{"issue":"16","key":"87_CR55","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","volume":"33","author":"LC Vark van","year":"2012","unstructured":"van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088\u201397. doi: 10.1093\/eurheartj\/ehs075 .","journal-title":"Eur Heart J"},{"issue":"11","key":"87_CR56","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","volume":"23","author":"M Tepel","year":"2008","unstructured":"Tepel M, Hopfenmueller W, Scholze A, Maier A, Zidek W. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transpl. 2008;23(11):3605\u201312. doi: 10.1093\/ndt\/gfn304 .","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"87_CR57","first-page":"710","volume":"108","author":"PATS Collaborating Group","year":"1995","unstructured":"PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl). 1995;108(9):710\u20137.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"87_CR58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/HYPERTENSIONAHA.107.089763","volume":"50","author":"JG Wang","year":"2007","unstructured":"Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50(1):181\u20138. doi: 10.1161\/HYPERTENSIONAHA.107.089763 .","journal-title":"Hypertension"},{"issue":"9287","key":"87_CR59","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative group","year":"2001","unstructured":"PROGRESS Collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033\u201341.","journal-title":"Lancet"},{"key":"87_CR60","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.","journal-title":"BMJ"},{"issue":"6","key":"87_CR61","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.112.194167","volume":"59","author":"BM Egan","year":"2012","unstructured":"Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124\u201331. doi: 10.1161\/HYPERTENSIONAHA.112.194167 .","journal-title":"Hypertension"},{"issue":"4","key":"87_CR62","doi-asserted-by":"crossref","first-page":"e92955","DOI":"10.1371\/journal.pone.0092955","volume":"9","author":"U Jadhav","year":"2014","unstructured":"Jadhav U, Hiremath J, Namjoshi DJ, Gujral VK, Tripathi KK, Siraj M, et al. Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. PLoS One. 2014;9(4):e92955. doi: 10.1371\/journal.pone.0092955 .","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.1007\/s40256-014-0103-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T00:00:00Z","timestamp":1420675200000}}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-014-0087-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-014-0087-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-014-0087-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:26Z","timestamp":1559489306000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-014-0087-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,28]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1007\/s40256-014-0087-y","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,28]]}}}